954 Stock Overview
A biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Awakn Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.063 |
| 52 Week High | CA$0.17 |
| 52 Week Low | CA$0.027 |
| Beta | 2.66 |
| 11 Month Change | -8.03% |
| 3 Month Change | -18.71% |
| 1 Year Change | -20.25% |
| 33 Year Change | -96.82% |
| 5 Year Change | n/a |
| Change since IPO | -95.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 954 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.8% | -0.7% | -0.02% |
| 1Y | -20.3% | -17.2% | 8.2% |
Return vs Industry: 954 underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 954 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 954 volatility | |
|---|---|
| 954 Average Weekly Movement | 75.2% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 954's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 954's weekly volatility has increased from 67% to 75% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Anthony Tennyson | awaknlifesciences.com |
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S–ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders; and with the University of Nottingham focusing on evaluating the company’s lead aminoindane series and its potential to enhance social cognition and pro-social behaviors.
Awakn Life Sciences Corp. Fundamentals Summary
| 954 fundamental statistics | |
|---|---|
| Market cap | €3.15m |
| Earnings (TTM) | -€1.97m |
| Revenue (TTM) | €56.63k |
60.7x
P/S Ratio-1.7x
P/E RatioIs 954 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 954 income statement (TTM) | |
|---|---|
| Revenue | CA$82.43k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$82.43k |
| Other Expenses | CA$2.95m |
| Earnings | -CA$2.87m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.069 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,479.83% |
| Debt/Equity Ratio | 0% |
How did 954 perform over the long term?
See historical performance and comparison